Cardioprotective effects of oxymatrine on isoproterenol-induced heart failure via regulation of DDAH/ADMA metabolism pathway in rats

European Journal of Pharmacology

Volumn 745, Issue , 2014, Pages 29-35

  Zhang, Wei ^a   Zhang, Jian ^a   Kang, Yansheng ^a   Liu, Jingjing ^a   Wang, Xiaoqing ^a   Xu, Qingbin ^b   Wang, Yilei ^a   Xu, Xiaoya ^a   Dai, Guidong ^a,c  

^a Second Affiliated Hospital of Yanan University   (China)

^b AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

^c Kaili University   (China)

Author keywords

ADMA; DDAH2; Heart failure; Isoproterenol; Oxymatrine

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DIMETHYLARGININASE; DIMETHYLARGININE DIMETHYLAMINOHYDROLASE 2; ISOPRENALINE; N(G),N(G) DIMETHYLARGININE; OXYMATRINE; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN ARGININE METHYLTRANSFERASE 1; TROPONIN I; UNCLASSIFIED DRUG;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG ACTIVITY; ENZYME METABOLISM; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HEART RATE; METABOLIC REGULATION; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UPREGULATION;

EID: 84918787213     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.10.001     Document Type: Article

References (27)

1. R.H. Böger, R. Maas, F. Schulze, and E. Schwedhelm Elevated levels of asymmetric dimethylarginine (ADMA) as a marker of cardiovascular disease and mortality Clin. Chem. Lab Med. 43 2005 1124 1129
2. C. Chen, and C.X. Chen Pharmacological research progress of oxymatrine on cardiovascular and cerebral diseases Chin. J. New Drugs Clin. Rem. 31 2012 295 299
3. V. De Gennaro Colonna, S. Bonomo, P. Ferrario, M. Bianchi, M. Berti, M. Guazzi, B. Manfredi, E.E. Muller, F. Berti, and G. Rossoni Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats Eur. J. Pharmacol. 557 2007 178 185
4. V. De Gennaro Colonna, M. Bianchi, V. Pascale, P. Ferrario, F. Morelli, W. Pascale, L. Tomasoni, and M. Turiel Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule Med. Sci. Monit. 15 2009 RA91 RA101
5. C. Dückelmann, F. Mittermayer, D.G. Haider, J. Altenberger, J. Eichinger, and M. Wolzt Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure Arterioscler. Thromb. Vasc. Biol. 27 2007 2037 2042
6. E. El-Demerdash, A.S. Awad, R.M. Taha, A.M El-Hady, and M.M. Sayed-Ahmed Probucol attenuates oxidative stress and energy decline in isoproterenol-induced heart failure in rat Pharmacol. Res. 51 2005 311 318
7. D. Grimm, D. Elsner, H. Schunkert, M. Pfeifer, D. Griese, G. Bruckschlegel, F. Muders, G.A. Riegger, and E.P. Kromer Development of heart failure following isoproterenol administration in the rat: role of renin-angiotensin system Cardiovas. Res. 37 1998 91 100
8. S. Hongli, L. Lei, S. Lei, Z. Dan, D. Deli, Q. Guofen, L. Yan, C. Wenfeng, and Y. Baofeng Cardioprotective effects and underlying mechanisms of oxymatrine against Ischemic myocardial injuries of rats Phytother. Res. 22 2008 985 989
9. S.T. Hu, Y. Tang, Y.F. Shen, H.H. Ao, J. Bai, Y.L. Wang, and Y.J. Yang Protective effect of oxymatrine on chronic rat heart failure J. Physiol. Sci. 61 2011 363 372
10. C.P. Hsu, S.J. Lin, M.Y. Chung, and T.M. Lu Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure Atherosclerosis 225 2012 504 510
11. P. Krenek, J. Kmecova, D. Kucerova, Z. Bajuszova, P. Musil, A. Gazova, P. Ochodnicky, J. Klimas, and J. Kyselovic Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function Eur. J. Heart Fail. 11 2009 140 146
12. Y. Liu, Y.P. Yang, and B. Zhong Research on the protective effect of oxymatrine in cardiac injury of rats induced by adriamycin Prog. Mod. Biomed. 13 2013 5267 5270
13. X.B. Li, R. Zhou, P. Zheng, and G.D. Dai Cardioprotective effect of matrine on isoproterenol-induced cardiotoxicity in rats J. Pharm. Pharmacol. 62 2010 514 520
14. X. Li, X. Wang, Y. Guo, N. Deng, P. Zheng, Q. Xu, Y. Wu, and G. Dai Regulation of endothelial nitric oxide synthase and asymmetric dimethylarginine by matrine attenuates isoproterenol-induced acute myocardial injury in rats J. Pharm. Pharmacol. 64 2012 1107 1108
15. Y. Pei, P. Ma, X Wang, W Zhang, X Zhang, P Zheng, L Yan, Q Xu, and G. Dai Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism Eur. J. Pharmacol. 666 2011 165 172
16. G. Riccioni, L. Speranza, L. Scotti, V. Bucciarelli, E. Di Ilio, N. D'Orazio, M. Pesce, A. Aceto, V. Sorrenti, A. Frigiola, and T. Bucciarelli The effect of pharmacological treatment on ADMA in patients with heart failure Front. Biosci. 3 2011 1310 1314
17. V.L. Roger Epidemiology of heart failure Circ. Res. 113 2013 646 659
18. Y. Sakata, and H. Shimokawa Epidemiology of heart failure in Asia Circ. J. 77 2013 2209 2217
19. F. Simko, K.R. Bednarova, K. Krajcirovicova, J. Hrenak, P. Celec, N. Kamodyova, L. Gajdosechova, S. Zorad, and M. Adamcova Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure J. Pineal. Res. 57 2014 177 184
20. X.C. Shen, Y.P. Yang, T.T. Xiao, J. Peng, and X.D. Liu Protective effect of oxymatrine on myocardial fibrosis induced by acute myocardial infarction in rats involved in TGF-β1-Smads signal pathway J. Asian Nat. Prod. Res. 13 2011 215 224
21. O. Tutarel, A. Denecke, S.M. Bode-Böger, J. Martens-Lobenhoffer, S. Lovric, J. Bauersachs, B. Schieffer, M. Westhoff-Bleck, and J.T. Kielstein Asymmetrical dimethylarginine - more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease PLoS One 7 2012 e33795
22. C. Wadham, and A.A. Mangoni Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease Expert Opin. Drug Metab. Toxicol. 5 2009 303 319
23. Y. Wang, Y.H. Xu, A.Q. Xiong, Y.N. Yuan, P. Zheng, P. Ma, G.D. Dai, and Q.B. Xu Protective effect of oxymatrine on chronic heart failure and ADMA metabolism pathway in isoproterenol-induced chronic heart failure in rats China J. Chin. Mater. Med. 39 2014 471 477
24. K.T. Weber, J.S. Janicki, and C.S. Maskin Pathophysiology of cardiac failure Am. J. Cardiol. 56 1985 3B 7B
25. K.T Weber, J.S. Janicki, and C. Campbell Pathophysiology of acute and chronic cardiac failure Am. J. Cardiol. 60 1987 3C 9C
26. X.Y. Yang, H. Xu, and T. Wang The investigation about protective mechanism of oxymatrine on cardiac function in rats with myocardial injury Chin. J. Med. Guide 9 2007 146 149
27. R. Zhou, Q.B. Xu, P. Zheng, L. Yan, J. Zheng, and G.D. Dai Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat Eur. J. Pharmacol. 586 2008 244 250